Statera Biopharma, Inc.
Statera Biopharma, Inc.
Your view on STAB
Overview
What the company does, where it operates, and who runs it.
About Statera Biopharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Blake Hawley
- Headquarters
- 2537 Research Boulevard, Fort Collins, CO, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Blake Hawley
- Headquarters
- 2537 Research Boulevard, Fort Collins, CO, US
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021.
The company is based in Fort Collins, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Statera Biopharma, Inc., and the rating behind it. STAB last traded at $0.0004; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Statera Biopharma, Inc.. Starting points for Statera Biopharma, Inc.: EPS -$4.97, beta -4.78 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Statera Biopharma, Inc.. Statera Biopharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Statera Biopharma, Inc.. Trailing twelve-month EPS for Statera Biopharma, Inc. stands at -$4.97. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Statera Biopharma, Inc.. Statera Biopharma, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Statera Biopharma, Inc. valued side by side against its closest peers. Statera Biopharma, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Statera Biopharma, Inc., and how their positions are changing. At a $28,566 market value, institutional positions materially move Statera Biopharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Statera Biopharma, Inc. executives and directors. Shares of Statera Biopharma, Inc. have traded between $0.0001 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Statera Biopharma, Inc.. Statera Biopharma, Inc. is a $28,566 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Statera Biopharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Statera Biopharma, Inc.. Coverage tracks Statera Biopharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.